News Cyxone AB

Equities

Market Closed - Nasdaq Stockholm Other stock markets 16:08:06 10/05/2024 BST			5-day change	1st Jan Change
0.1095 ^SEK	+6.83%		+23.03%	+9.06%

04-22	Sweden's Cyxone Appoints New CEO	MT
04-22	Cyxone AB Announces Chief Executive Officer Changes	CI

Sweden's Cyxone Appoints New CEO	04-22	MT
Kjell Stenberg new CEO in Cyxone AB	04-22	AQ
Cyxone AB Announces Chief Executive Officer Changes	04-22	CI
BioStock: Cyxone comments on the clinical collaboration in the UK	03-28	AQ
Cyxone Enters Research Deal for Rheumatoid Arthritis Therapy	03-25	MT
Cyxone enters important research collaboration	03-25	AQ
Cyxone Enters Important Research Collaboration with University of Glasgow	03-25	CI
BioStock: Cyxone's CEO gives a status update	03-05	AQ
Cyxone AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-27	CI
BioStock: Cyxone identifies target protein for rabeximod	01-17	AQ
Cyxone reaches important milestone regarding mechanism of action	01-15	AQ
Cyxone Reaches an Important Milestone for the Drug Candidate Rabeximod	01-15	CI
Cyxone welcomes a renewed engagement by Professor Rikard Holmdahl as Scientific Advisor	11-20	AQ
Interim Report 1 January to 30 September 2023	27/10/23	AQ
Cyxone AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	27/10/23	CI
Cyxone to Receive Unitary Patent in EU for T20K Drug Candidate	09/10/23	MT
Cyxone receives Intention to Grant from the European Patent Office for a unitary patent of T20K	09/10/23	AQ
BioStock Investor Meeting: Cyxone	27/09/23	AQ
Interim Report 1 January to 30 June 2023	30/08/23	AQ
Cyxone AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	30/08/23	CI

No results for this search